Clinical Review Recent developments

Travel medicine

BMJ 2002; 325 doi: http://dx.doi.org/10.1136/bmj.325.7358.260 (Published 03 August 2002) Cite this as: BMJ 2002;325:260
  1. Jane N Zuckerman, senior lecturer. (j.zuckerman{at}rfc.ucl.ac.uk)
  1. Academic Centre for Travel Medicine and Vaccines, Royal Free and University College Medical School, London NW3 2PF
  • Accepted 23 May 2002

Travel medicine is an exciting interdisciplinary specialty that has developed rapidly in response to the needs of the travelling population worldwide. International arrivals worldwide by any form of transport were around 664 million in 2000 (fig 1), and the World Tourist Organisation has predicted an 80% increase in travel to long haul destinations between 1995 and 2010.12 Specialists in travel medicine consider diverse aspects of travel related health, including fitness to travel and the health risks of travelling in itself, as well as the implications of exposure to a variety of infectious diseases. This review highlights current topical issues in this evolving specialty.

Sources and search criteria

This article is based on information from several sources, including a review of the literature obtained from the PubMed database, clinical experience, and textbooks on the subject of travel medicine.

The development of travel medicine as a distinct discipline

The development of travel medicine as a discipline is a recent advance in itself.4 This has been recognised in the United Kingdom by the Department of Health in its new strategy for combating infectious disease, which confirms the need for specialists in travel medicine.5

An important organisational development has been the establishment of dedicated specialist travel health clinics in teaching hospitals and primary care (in addition to clinics operated by independent commercial groups). These provide individual pretravel risk assessments (box 1) and should improve services for patients, many of whom seldom seek health advice before travel.6 The importance of providing services for patients is increasingly being recognised in relation to an increased incidence of travel related disease (box 2)and importation of infection (fig 2).7

Recent developments

Travel medicine is developing as a new specialty providing specialist travel services to meet the health needs of vastly increasing numbers of travellers

A pretravel risk assessment allows travel health related risk factors to be identified

The public health implications of the growing number of refugees and migrants from less developed to developed countries need to be fully assessed, and appropriate services need to be provided

Vector borne diseases, in particular malaria, remain an important health risk

The appropriate use of malaria standby treatment may become an option for experienced travellers

New combination vaccines that can be administered by an accelerated schedule are a welcome advance in combating infectious disease

Assessment of fitness to fly and awareness of the possible physiological and psychological impacts of air travel should be considered

The International Society of Travel Medicine and the British Travel Health Association (UK) provide information and support to health professionals who are offering travel advisory services to patients. Information from the International Society of Travel Medicine is available on the internet and includes a comprehensive and international listing of travel medicine specialists and travel health clinics. Guidelines and information relating to the discipline of travel medicine are also available from the World Health Organization, the Department of Health, and the Centers for Disease Control and Prevention, as well as from the recently formed European Travel Health Advisory Board (see additional educational resources).8

Training in the discipline is available both nationally and internationally through certification, diploma, or masters degrees (see bmj.com). A new initiative from the International Society of Travel Medicine includes a certificate in travel medicine that encompasses a body of knowledge in travel medicine developed by an international group of travel medicine physicians.

Refugees and migrants

International migration, usually from poor countries to rich countries, is a worldwide phenomenon. Estimates put the number of migrants worldwide in 1990 in excess of 120 million, with an annual growth rate of 1.9%.9 Net international migration contributed to 45% of the population growth in the developed world and almost 88% of the population growth in Europe in 1990-5. The number of refugees worldwide, including asylum seekers, in 2001 totalled 19.8 million.10 Trafficking in migrants has become a lucrative illegal market.

The migration process has important health implications. Migrants often have a higher rate than other travellers of conditions such as tuberculosis, hepatitis B and C, schistosomiasis, malaria, and sexually transmitted infections (including syphilis and HIV). They also have a higher rate of non-infectious conditions such as diabetes, cardiovascular disease, malignant diseases, asthma, respiratory diseases linked to smoking, occupational diseases, and injuries, as well as psychological disorders.11 Stress related health problems are exacerbated by changes in lifestyle, food habits, culture, and religious life. As the number of refugees and migrants grows, medical providers and travel medicine physicians need to understand and respond to the wide range of health problems they have.

Fig 1
Fig 1

Percentage increase in international arrivals between 1993 and 19973

Pretravel risk assessment

• Detailed itinerary:

  • Countries and regions

  • Urban, rural, or jungle

  • Purpose of travel

  • Mode of travel

  • Type of accommodation

  • Duration of stay and travel

•Consider:

  • Special activities

  • Special needs

  • Special high risks

  • Previous travel

  • Available medical facilities

  • Detailed medical history

  • Concurrent medications

  • Personal immunisation history

  • Appropriate immunisations and malaria prophylaxis

RETURN TO TEXT

Key travel related health problems

  • Travellers' diarrhoea

  • Malaria

  • Respiratory tract infections

  • Hepatitis A and B

  • Skin infections

  • Sexually transmitted infections

RETURN TO TEXT
Fig 2
Fig 2

Cases of falciparum malaria in the United Kingdom, 1990-95

Vector borne disease

Up to 8 in 1000 travellers in developed countries become infected with malaria, resulting in more than 10 000 cases of malaria being imported into Europe each year (fig 2).1213 Other vector borne diseases, such as dengue and yellow fever, are also increasingly important.14

Since December 2001, following the report of six deaths possibly associated with the administration of yellow fever vaccine in elderly travellers, health professionals have expressed concern about the use of yellow fever vaccine.1517 Millions of doses of vaccine have been administered over many years, however, with a minimum risk of morbidity or mortality, and experts agree that the benefits of yellow fever vaccination outweigh the risks.

Malaria remains the single most important disease hazard facing travellers. Adherence to antimalarial chemoprophylaxis, in addition to adopting measures to avoid being bitten, is essential. Chloroquine resistant falciparum malaria is an increasing problem in Central and South America, South East Asia, Oceania, and sub-Saharan Africa.18 Recommended prophylaxis for chloroquine resistant areas, to be discussed with the individual traveller, include mefloquine, doxycycline, and atovaquone plus proguanil (Malarone). Chloroquine continues to be recommended as prophylaxis for malaria in areas where there is no chloroquine resistance.

It is advisable for people taking mefloquine for the first time to start three weeks before departure so that if they experience side effects such as anxiety or nightmares alternative prophylactic drugs can be considered. Alternatives include Malarone one tablet daily, doxycycline 100 mg daily, dapsone plus pyrimethamine (Maloprim) one tablet weekly or chloroquine and proguanil. Malarone consists of 250 mg atovaquone and 100 mg proguanil and is of particular value for people travelling to chloroquine resistant areas.19 Prophylaxis should be started one day before entry into an endemic area and continued for seven days after leaving it.

Guidance on antimalarial chemoprophylaxis has recently been issued by the Advisory Committee on Malaria Prevention for UK Travellers (box 3). Malarone, doxycycline, and mefloquine are recommended in chloroquine resistant areas. Mefloquine is recommended for travel of longer than two weeks' duration to West, Central, and East Africa and specific areas of South East Asia. Chloroquine and proguanil are recommended for travel to other areas.20

Malaria chemoprophylaxis by continent (depending on season and area visited

The Advisory Committee on Malaria Prevention for UK Travellers recommends

  • North Africa and Middle East—chloroquine alone or chloroquine plus proguanil

  • Sub-Saharan Africa—mefloquine, doxycycline, or atovaquone plus proguanil

  • South Asia—chloroquine plus proguanil

  • South East Asia—mefloquine, doxycycline, or atovaquone plus proguanil (Indonesia and forests of Malaysia and Sarawak—chloroquine plus proguanil)

  • Oceania—mefloquine, doxycycline, or atovaquone plus proguanil

  • Latin America—mefloquine, doxycycline, or atovaquone plus proguanil

  • Caribbean—chloroquine plus proguanil or chloroquine alone

Malaria chemoprophylaxis regimens

  • Chloroquine—two tablets taken weekly starting a week before travel to endemic area and continuing for four weeks after leaving malarious area

  • Proguanil—one tablet daily starting a week before travel to endemic area and continuing for four weeks after leaving malarious area

  • Doxycycline—one tablet daily starting one day before travel to endemic area and continuing for four weeks after leaving malarious area

  • Atovaquone plus proguanil (Malarone)—one tablet daily starting one day before travel to endemic area and continuing for seven days after leaving malarious area

  • Mefloquine—one tablet weekly starting trial dose three weeks before departure if appropriate and continuing for four weeks after leaving malarious area

RETURN TO TEXT

Standby treatment in defined circumstances may become of increasing value to travellers. Standby treatment consists of a course of antimalarial drugs that travellers to malaria endemic areas can use for self treatment if they are unable to gain access to medical advice within 24 hours of becoming unwell. The treatment kits are supplied with written instructions, and travellers must seek medical advice as soon as possible. Recently licensed agents indicated for use as standby treatment include Malarone and Riamet, which is a new fixed dose antimalarial drug containing 20 mg artemether and 120 mg lumefantrine.21

Prevention of infectious disea

The prevention of infectious disease in travellers continues to receive substantial consideration, as an appreciable number of such diseases are now considered to be “vaccine preventable.”22 Vaccines usually recommended for general travel include tetanus, poliomyelitis, and hepatitis A. As destinations become more diverse, with people increasingly travelling outside Europe, additions to this list include typhoid, hepatitis B, diphtheria, and rabies (box 4). Mandatory vaccines, for which certification is often necessary, include yellow fever and meningoccocal meningitis, as appropriate to the destination. Travellers at high risk, such as those with chronic medical problems, would benefit from vaccination against diseases such as influenza, whose seasonal prevalence differs in temperate and tropical climates, as well as pneumococcal vaccine and hepatitis B vaccine.

Vaccines for travellers

Routine

  • Poliomyelitis

  • Tetanus

  • Childhood immunisations (in date

  • Recommended for travel outside northwest Europe, North America, Australia, and New Zealand:

  • Diphtheria (travellers in close contact with the indigenous population)

  • Hepatitis A

  • Hepatitis B

  • Typhoid

Special risk

  • Influenza (travellers with underlying medical problems)

  • Japanese encephalitis (travel for more than four weeks in rural area

  • Meningoccocal meningitis (travellers in close contact with the indigenous population)

  • Pneumococcus (travellers with underlying medical problems)

  • Rabies (rural travel and travel more than 24 hours away from medical help)

  • Tick borne encephalitis (travel to forested areas of Eastern Europe)

Certificate required

  • Meningoccocal meningitis (travel to Saudi Arabia for purposes of a pilgrimage)

  • Yellow fever (travel to parts of sub-Saharan Africa and parts of Central and South America)

RETURN TO TEXT

Rapid schedules of vaccination

  • Hepatitis B (Engerix B)—days 0, 7, and 21; booster at 12 months

  • Hepatitis A and B (Twinrix)—days 0, 7, and 21; booster at 12 months

Combination vaccines

  • Hepatitis A and B (Twinrix)

  • Hepatitis A and typhoid (Hepatyrix; ViATIM)

  • Diphtheria and tetanus (DT, d, Td)

Additional educational resources

  • Bradley DJ, Bannister B. Guidelines for malaria prevention in travellers from the United Kingdom for 2001.Commun Dis Public Health2001;4:84-101

  • Department of Health.Health information for overseas travel 2001. London: Department of Health, 2001

  • World Health Organization.International travel and health 2002. Geneva: WHO, 2002

  • Zuckerman JN, ed.The principles and practice of travel medicine. Chichester: John Wiley & Sons, 2001

Websites

BMJarchive

  • Mortimer P. Yellow fever vaccine.BMJ2002;324:439

  • Goodwin T. In-flight medical emergencies: an overview.BMJ2000;321:1338-41

  • Webster G, Barnes E, Dusheiko G, Franklin I. Protecting travellers from hepatitis A. BMJ2001;322:1194-5

Hepatitis B vaccine should also be considered for a wider range of travellers, including those who may travel to areas endemic for hepatitis B, may be exposed by virtue of their sexual practices, or may be exposed to unscreened or inadequately screened blood or blood products or inadequately sterilised medical and surgical equipment.23

People are increasingly travelling at short notice, and the ability to provide good levels of protection within a period of four weeks is an important development. Newer combination vaccines, such as hepatitis A plus typhoid and hepatitis A plus B, provide dual protection by a single injection (box 5). This increases uptake and convenience (particularly for people with a fear of needles) and by using only one site makes another injection site available when time is short and multiple immunisations need to be considered. Rapid schedules of vaccination include monovalent hepatitis B vaccine, which can be administered according to three different schedules, and combined hepatitis A and B vaccine, which can be administered as a primary course within three weeks.24

Other recent developments include the introduction of a quadrivalent meningoccocal meningitis vaccine to protect against the W135 strain, which has been associated with several outbreaks of disease in Saudi Arabia as well as in parts of sub-Saharan Africa.25 Other new vaccines licensed in the United States include a vaccine against varicella.26

Figure3

The increase in air travel has led to increases in the incidence of travel related disease and the importation of infection

Credit: PETER MACDIARMID/REX

As part of the expanded programme on immunisation, under the auspices of the WHO, worldwide eradication of poliomyelitis remains a goal. The report of outbreaks of vaccine associated poliomyelitis in countries where wild poliovirus has been eliminated is, however, of concern.27 In view of this, it would seem prudent for those travellers at particular risk—for example, those in contact with the local population, such as aid workers—to maintain levels of protection against poliomyelitis.

Aviation medicine

Health practitioners need to be aware of the health effects of reduced atmospheric pressure, transmeridian travel (causing jetlag), and motion sickness and to consider passengers' fitness to travel by air. Guidelines for medical clearance, in-flight medical emergencies, and aircraft emergency medical equipment have been reviewed.28

The risk of transmission of respiratory diseases in association with air travel should also be considered. No case of active tuberculosis as a result of exposure during travel by air has yet been identified, but transmission of Mycobacterium tuberculosismay occur during flights of more than eight hours, as the risk of infection is related to the proximity and duration of exposure to the source patient.29

Considerable attention has been given to travel related deep vein thrombosis. 30 31 The estimated risk of developing deep vein thrombosis after a long distance flight is between 0.1 and 0.4 per thousand of the general population.32 Methods of preventing deep vein thrombosis, including identification of travellers with predisposing risk factors,32 are important. All passengers, regardless of their risk, should move around in their seats and in the aircraft cabin as much as possible during the journey. Drinks containing alcohol or caffeine should be avoided before and during the flight, and water or soft drinks should be taken to reduce the effects of dehydration. Exercising the calf muscles every half hour while seated by spending a few minutes flexing and rotating the ankles is also recommended to reduce the effects of stasis.

The prophylactic use of aspirin, and in some cases subcutaneous heparin, to prevent deep vein thrombosis is under discussion. Under the auspices of the WHO, studies are planned to evaluate the risk of deep vein thrombosis associated with travelling by air. The aims of the research programme are to determine the frequency and cause of travellers' thrombosis through epidemiological studies, to identify who is at greatest risk through pathophysiological studies, and to undertake clinical studies that will focus on the effectiveness of possible preventive strategies.33

Footnotes

  • Competing interests JNZ has been reimbursed by several manufacturers of vaccines and antimalarial prophylaxis for attending conferences and running educational programmes and has received unrestricted educational grants. JNZ is also a consultant in travel medicine to British Airways travel clinics

    Details of courses in travel medicine appear on bmj.com

    Embedded Image

References